Randomized, double-blind Phase II study of Docetaxel + Sorafenib (Nexavar) versus Docetaxel + Placebo in First-Line treatment of patients with HER2-negative, metastatic breast cancer.
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2014
At a glance
- Drugs Sorafenib (Primary) ; Docetaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms MADONNA
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 23 Mar 2013 Status changed from recruiting to suspended as reported by European Clinical Trials Database.
- 16 Jan 2013 New source identified and integrated (German Clinical Trials Register record: DRKS00003947).